NovoCure (NVCR) COO has 2,133 shares withheld for RSU taxes

Rhea-AI Filing Summary

NovoCure Ltd’s Chief Operating Officer, Paravasthu Mukund, reported an automatic share withholding related to equity compensation. On 01/11/2026, 2,133 ordinary shares were withheld by the company at a price of $14.35 per share to cover tax obligations arising from the vesting of Restricted Stock Units.

After this non-discretionary tax-withholding transaction, Mukund beneficially owns 78,306 ordinary shares directly. The withholding was approved as required under Rules 16b-3(e) and 16b-3(d)(1), and reflects routine tax handling of vested stock-based awards rather than an open-market sale.

Insider Trade Summary

Net Seller: 2,133 shares

Net Sell 1 txn

Insider Paravasthu Mukund

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Ordinary Shares	2,133	$14.35	$31K

Holdings After Transaction: Ordinary Shares — 78,306 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).

FAQ

What insider transaction did NovoCure (NVCR) report for Paravasthu Mukund?

NovoCure’s Chief Operating Officer, Paravasthu Mukund, reported an automatic withholding of 2,133 ordinary shares on 01/11/2026 to cover tax obligations from vesting Restricted Stock Units.

Was the NVCR COO’s Form 4 transaction a discretionary share sale?

No. The Form 4 states that the 2,133 shares represent shares required to be withheld by the issuer to satisfy tax withholding on vested Restricted Stock Units, and that the transaction is not discretionary.

At what price were NovoCure (NVCR) shares withheld for taxes?

The tax-withholding transaction for COO Paravasthu Mukund used a price of $14.35 per share for the 2,133 ordinary shares withheld.

How many NovoCure (NVCR) shares does the COO hold after this Form 4 transaction?

Following the reported tax-withholding transaction, Paravasthu Mukund beneficially owns 78,306 ordinary shares of NovoCure Ltd, held directly.

What is the role of the reporting person in this NovoCure (NVCR) Form 4 filing?

The reporting person, Paravasthu Mukund, is identified as an officer of NovoCure Ltd, serving as Chief Operating Officer, and is neither a director nor a 10% owner.

How is the RSU vesting transaction for NovoCure (NVCR) classified on Form 4?

The RSU-related tax withholding is coded as transaction “F” for Ordinary Shares in Table I, indicating shares withheld by the issuer to pay taxes upon vesting of equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/12/2026 - 05:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paravasthu Mukund

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	01/11/2026		F		2,133(1)	D	$14.35	78,306	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).

Remarks:

	Steven Robbins, as attorney in fact for Paravasthu, Mukund	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.